Close

Join us for a day of learning and connecting Register Free Today

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

Immunotherapy for Prostate Cancer

On September 30, 2014, Charles G. Drake, M.D., Ph.D., an associate professor of oncology, urology, and immunology at  the Johns Hopkins School of Medicine, discussed current immunotherapy treatment options for patients with prostate cancer, and how close we are to making these treatments available to more patients.

Dr. Drake also serves as co-director of the Prostate Cancer Multidisciplinary Clinic. His areas of expertise include immunotherapy and the diagnosis and treatment of cancers of the prostate, kidney, bladder, and testes. Dr. Drake graduated with a B.S. in electrical engineering and M.S. in biomedical engineering from Rutgers University. He then received a Ph.D. in immunology from the National Jewish Center for Immunology, and in 1997 completed an M.D. at the University of Colorado Health Sciences Center. He conducted an internal medicine residency on the Osler Service at Johns Hopkins, and in 2002 he completed a fellowship in medical oncology, also at Johns Hopkins. He joined the Johns Hopkins faculty as an assistant professor in 2002. Dr. Drake has published extensively, has won numerous awards and honors for his research and scholarship, and holds several patent.

This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This webinar was generously supported by Dendreon. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.

*Immunotherapy results may vary from patient to patient.

Contact Us

National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Top